[Clinical and pharmacoeconomic aspects of the antisecretory therapy of gastroesophageal refluxed disease].
The article discloses the results of an open prospective randomized study of the antisecretory therapy efficiency conducted among 20 patients with gastroesophageal refluxed disease (erosive form, non-complicated course). The selection of the optimal antisecretory drug was substantiated from the point of view of the clinic-diagnostic and pharmacoeconomic assessment of the results of the above-mentioned therapy conducted with the application of rabeprosole (pariet) and its generic omeprosole (omez).
Livzan
M A
MA
Kononov
A V
AV
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004945:Esophagoscopy; D005744:Gastric Acid / Q000378:metabolism*; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D009853:Omeprazole